Alopecia - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 168
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A7F898B0CE3EN
Leaflet:

Download PDF Leaflet

Alopecia - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Alopecia - Pipeline Review, H2 2016’, provides an overview of the Alopecia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Alopecia
  • The report reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Alopecia therapeutics and enlists all their major and minor projects
  • The report assesses Alopecia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Alopecia
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alopecia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Alopecia Overview
Therapeutics Development
Pipeline Products for Alopecia - Overview
Pipeline Products for Alopecia - Comparative Analysis
Alopecia - Therapeutics under Development by Companies
Alopecia - Therapeutics under Investigation by Universities/Institutes
Alopecia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Alopecia - Products under Development by Companies
Alopecia - Products under Investigation by Universities/Institutes
Alopecia - Companies Involved in Therapeutics Development
Ache Laboratorios Farmaceuticos S/A
Aclaris Therapeutics, Inc.
Allergan Plc
Almirall, S.A.
AndroScience Corporation
Berg LLC
BiologicsMD, Inc.
Bristol-Myers Squibb Company
Concert Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc.
Follicum AB
Handok Inc.
Histogen, Inc.
Hyundai Pharmaceutical Co., Ltd.
Incyte Corporation
Kuhnil Pharmaceutical Co., Ltd.
Lee's Pharmaceutical Holdings Limited
LEO Pharma A/S
NovaLead Pharma Pvt. Ltd.
Novartis AG
Panacea Biotec Limited
Quark Pharmaceuticals, Inc.
RepliCel Life Sciences, Inc.
RXi Pharmaceuticals Corporation
Sucampo Pharmaceuticals, Inc.
SWITCH Biotech LLC
Taisho Pharmaceutical Holdings Co., Ltd.
TetraLogic Pharmaceuticals
Tigo GmbH
Valeant Pharmaceuticals International, Inc.
Vida Therapeutics Inc.
Alopecia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept - Drug Profile
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
Antisense Oligonucleotide to Antagonize Androgen Receptor for Alopecia - Drug Profile
ASCJ-9 - Drug Profile
ATI-50001 - Drug Profile
ATI-50002 - Drug Profile
bimatoprost - Drug Profile
BMD-1141 - Drug Profile
BMD-1341 - Drug Profile
BMD-2341 - Drug Profile
BQ-A - Drug Profile
BRM-421 - Drug Profile
calcitriol - Drug Profile
CB-0301 - Drug Profile
CTP-543 - Drug Profile
DHL-HisZnNa - Drug Profile
diphencyprone - Drug Profile
finasteride - Drug Profile
finasteride - Drug Profile
FOL-005 - Drug Profile
FS-2 - Drug Profile
Hair Stimulating Complex - Drug Profile
HL-5945 - Drug Profile
HTB-005 - Drug Profile
interferon beta-1b - Drug Profile
KI-1104 - Drug Profile
KI-1105 - Drug Profile
LEO-124249 - Drug Profile
minoxidil - Drug Profile
NLP-602 - Drug Profile
OLX-104 - Drug Profile
PDI-38 - Drug Profile
QPAL-1 - Drug Profile
QPAL-2 - Drug Profile
RCH-01 - Drug Profile
Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and Graft Arteriosclerosis - Drug Profile
remetinostat - Drug Profile
RES-440 - Drug Profile
RK-023 - Drug Profile
ruxolitinib phosphate - Drug Profile
secukinumab - Drug Profile
setipiprant - Drug Profile
SM-04554 - Drug Profile
Small Molecule for Androgenic Alopecia - Drug Profile
Small Molecules to Inhibit JAK for Alopecia Areata and Androgenetic Alopecia - Drug Profile
Small Molecules to Inhibit JAK3 for Alopecia and Dermatological Disorders - Drug Profile
Synthetic Peptide for Alopecia - Drug Profile
TASP-0382088 - Drug Profile
VTI-1000 Series - Drug Profile
ZK-003 - Drug Profile
Alopecia - Dormant Projects
Alopecia - Discontinued Products
Alopecia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Alopecia, H2 2016
Number of Products under Development for Alopecia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Alopecia - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
Alopecia - Pipeline by Aclaris Therapeutics, Inc., H2 2016
Alopecia - Pipeline by Allergan Plc, H2 2016
Alopecia - Pipeline by Almirall, S.A., H2 2016
Alopecia - Pipeline by AndroScience Corporation, H2 2016
Alopecia - Pipeline by Berg LLC, H2 2016
Alopecia - Pipeline by BiologicsMD, Inc., H2 2016
Alopecia - Pipeline by Bristol-Myers Squibb Company, H2 2016
Alopecia - Pipeline by Concert Pharmaceuticals, Inc., H2 2016
Alopecia - Pipeline by Diffusion Pharmaceuticals Inc., H2 2016
Alopecia - Pipeline by Follicum AB, H2 2016
Alopecia - Pipeline by Handok Inc., H2 2016
Alopecia - Pipeline by Histogen, Inc., H2 2016
Alopecia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
Alopecia - Pipeline by Incyte Corporation, H2 2016
Alopecia - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H2 2016
Alopecia - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
Alopecia - Pipeline by LEO Pharma A/S, H2 2016
Alopecia - Pipeline by NovaLead Pharma Pvt. Ltd., H2 2016
Alopecia - Pipeline by Novartis AG, H2 2016
Alopecia - Pipeline by Panacea Biotec Limited, H2 2016
Alopecia - Pipeline by Quark Pharmaceuticals, Inc., H2 2016
Alopecia - Pipeline by RepliCel Life Sciences, Inc., H2 2016
Alopecia - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
Alopecia - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Alopecia - Pipeline by SWITCH Biotech LLC, H2 2016
Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
Alopecia - Pipeline by TetraLogic Pharmaceuticals, H2 2016
Alopecia - Pipeline by Tigo GmbH, H2 2016
Alopecia - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
Alopecia - Pipeline by Vida Therapeutics Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Alopecia - Dormant Projects, H2 2016
Alopecia - Dormant Projects (Contd..1), H2 2016
Alopecia - Dormant Projects (Contd..2), H2 2016
Alopecia - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Alopecia, H2 2016
Number of Products under Development for Alopecia - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

Ache Laboratorios Farmaceuticos S/A
Aclaris Therapeutics, Inc.
Allergan Plc
Almirall, S.A.
AndroScience Corporation
Berg LLC
BiologicsMD, Inc.
Bristol-Myers Squibb Company
Concert Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc.
Follicum AB
Handok Inc.
Histogen, Inc.
Hyundai Pharmaceutical Co., Ltd.
Incyte Corporation
Kuhnil Pharmaceutical Co., Ltd.
Lee's Pharmaceutical Holdings Limited
LEO Pharma A/S
NovaLead Pharma Pvt. Ltd.
Novartis AG
Panacea Biotec Limited
Quark Pharmaceuticals, Inc.
RepliCel Life Sciences, Inc.
RXi Pharmaceuticals Corporation
Sucampo Pharmaceuticals, Inc.
SWITCH Biotech LLC
Taisho Pharmaceutical Holdings Co., Ltd.
TetraLogic Pharmaceuticals
Tigo GmbH
Valeant Pharmaceuticals International, Inc.
Vida Therapeutics Inc.
Skip to top


Androgenic Alopecia - Pipeline Review, H2 2014 US$ 1,600.00 Dec, 2014 · 56 pages
Androgenic Alopecia - Pipeline Review, H1 2014 US$ 1,500.00 Jun, 2014 · 53 pages
C3 Jian, Inc - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 28 pages
Arterial Thrombosis - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 61 pages

Ask Your Question

Alopecia - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: